Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Terminated
AIM ImmunoTech Inc.
Phase 2
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in
HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml
(PCR).
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Terminated
Hemispherx Biopharma
Phase 2
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in
HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml
(PCR).
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Completed
AIM ImmunoTech Inc.
Phase 2
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic
Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA < 50 copies/ml (PCR)
and CD4 levels > 400.
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Completed
Hemispherx Biopharma
Phase 2
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic
Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA < 50 copies/ml (PCR)
and CD4 levels > 400.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
